Patent Search
 
Hair Loss Patent

Process for retarding hair loss and for inducing and stimulating its growth

Hair loss abstract


Compositions intended for use for retarding hair loss and for inducing and stimulating its growth, containing 2-aminopyrimidine 3-oxide derivatives, and new compounds derived from 2-aminopyrimidine 3-oxide. Composition for retarding hair loss and for inducing and stimulating its growth, containing at least one compound of formula: ##STR1## where R denotes H, alkyl or a ring of formula: ##STR2## X denotes ##STR3## with: R.sub.1 and R.sub.3 denote H, alkyl, optionally substituted, alkenyl, cycloalkyl, aralkyl or aryl of formula: ##STR4## where R.sub.9 and R.sub.10 denote H, alkyl, hydroxyl, alkoxy or halogen; or form a heterocycle with the nitrogen; R.sub.3 denotes alkyl, alkenyl, cycloalkyl, aralkyl, optionally substituted phenyl; R.sub.4 is identical to R.sub.3 ; Y denotes O or --OSO.sub.3.sup..crclbar. ; R' denotes H or ##STR5## R.sub.5 and R.sub.6 are alkyl; R.sub.7 and R.sub.8 denote H or alkyl; or its physiologically acceptable addition salts with acids.

Hair loss claims


We claim:

1. A process for retarding hair loss and for inducing and stimulating its growth comprising topically applying an effective amount of a composition containing, in a physiologically acceptable medium, at least one compound corresponding to the formula: ##STR36## in which: R denotes a saturated linear C.sub.1 -C.sub.8 alkyl radical;

X is selected from the group consisting of:

(i) a group ##STR37## in which: R.sub.1 and R.sub.2, which may be identical or different, denote a hydrogen atom, a saturated linear or branched C.sub.1 -C.sub.12 alkyl group which can be substituted with a halogen atom or a trifluoromethyl radical, a linear C.sub.7 -C.sub.12 aralkyl group or an aryl group corresponding to the formula: ##STR38## in which R.sub.9 and R.sub.10, which may be identical or different, denote hydrogen, C.sub.1 -C.sub.4 alkyl, hydroxyl, C.sub.1 -C.sub.4 alkoxy or halogen;

R.sub.1 and R.sub.2, with the nitrogen atom to which they are attached, can form a saturated or unsaturated heterocycle selected from the group consisting of aziridino, azetidino, pyrrolidino, piperidino, hexamethylenimino, heptamethylenimino octamethylenimino, tetrahydropyridino, dihydropyridino, pyrrole, pyrrazole, imidazole, triazole, 4-alkylpiperazino, morpholino, and thiomorpholino;

(ii) a group --OR.sub.3, in which:

R.sub.3 denotes a saturated linear or branched C.sub.1 -C.sub.12 alkyl radical; and

(iii) a group --SR.sub.4, in which R.sub.4 has the same meaning as R.sub.3 ; and

Y denotes an oxygen atom or an --OSO.sub.3.sup..crclbar. group; or a physiologically acceptable acid addition salt thereof.

2. The process according to claim 1, wherein the composition is in the form of an ointment, tincture, cream, pomade, powder patch, impregnated pad, solution, emulsion, vesicular dispersion, lotion, gel, spray or anhydrous or aqueous suspension, for the purpose of its pharmaceutical application.

3. The process according to claim 1, wherein the composition is a pharmaceutical composition in which the compound of formula (I) is present at concentrations of between 0.1 and 10% by weight relative to the total weight of the composition.

4. The process according to claim 3 wherein the concentration of the compound of formula I is between 0.2 and 5% by weight.

5. The process according to claim 1, wherein the composition is a cosmetic composition presented in the form of a lotion, gel, soap, shampoo, aerosol or foam, and containing, in a vehicle acceptable from a cosmetic standpoint, at least one compound of formula (I) at a concentration of between 0.01 and 5% by weight.

6. The process according to claim 5 wherein the concentration of the compound of formula I is between 0.05 and 3% by weight.

7. The process according to claim 1, wherein the composition is a composition containing in addition, hydrating agents and antiseborrhoeic agents.

8. The process according to claim 1, wherein the composition is a composition containing agents further improving the activity of the compounds of formula (I) with respect to hair regrowth and/or to retarding its loss.

9. The process according to claim 8, wherein the composition is a composition containing, by way of agents further improving the activity of hair regrowth and/or of retarding its loss, at least one member selected from a group consisting of a nicotinic acid ester, a steroidal or non-steroidal anti-inflammatory agent, a retinoid, an antibacterial agent, a calcium antagonist, a hormone, an anti-androgen, and an OH radical-trapping agent.

10. The process according to claim 9, wherein the composition is a composition containing, by way of compounds further improving the activity with respect to hair regrowth and/or to retarding its loss, at least one compound selected from a group consisting of diazoxide, spiroxasone, phospholipid, linoleic acid, linolenic acid, salicylic acid or salicylic acid derivative, hydroxy-carboxylic acid, keto-carboxylic acid, their esters and lactones and their corresponding salts, anthralin, carotenoid and 5, 8, 11, 14-eicosatetraynoic acid and 5, 8, 11-eicosatriynoic acid, their esters and amides.

11. The process according to claim 1, wherein the composition is a composition further comprising surfactants selected from nonionic and amphoteric surfactants.

12. The process according to claim 1, wherein the composition is a composition in which the physiologically acceptable medium consists of water or a mixture of water and one or more organic solvent(s), or of a mixture of organic solvents, the organic solvents being pharmaceutically or cosmetically acceptable.

13. The process according to claim 1, wherein the composition is a composition in which the solvents are selected from C.sub.1 -C.sub.4 lower alcohols, alkylene glycols and mono- and dialkylene glycol alkyl ethers.

14. The process according to claim 1, wherein the composition is a composition in which the physiologically acceptable medium is thickened by means of thickening and/or gelling agents, and contains preservatives, stabilizers, pH regulators, osmotic pressure-modifying agents, emulsifiers, UV-A and UV-B screening agents, and antioxidants.

15. The process according to claim 1 for the therapeutic treatment of alopecia, pelade, hair loss and desquamating dermatitis wherein the composition is a pharmaceutical composition applied to the hair and scalp in a therapeutically effective amount.

16. The process according to claim 1 for the cosmetic treatment of hair and scalp wherein the composition is a cosmetic composition applied to the hair and scalp in a cosmetically effective amount.

17. A pharmaceutical or cosmetic composition intended for use in topical application, containing, in a physiologically acceptable medium, at least one compound of formula (I') ##STR39## in which: R denotes a saturated linear C.sub.1 -C.sub.8 alkyl radical;

Y denotes an oxygen atom or an --OSO.sub.3.sup.3 group; and

X is selected from the group consisting of:

(i) a group SR.sub.4, in which R.sub.4 denotes a saturated linear or branched C.sub.1 -C.sub.12 alkyl radical; and

(ii) a group --OR.sub.3 in which R.sub.3 has the same meaning as R.sub.4, on condition that Y denotes an --OSO.sub.3.sup.3 group; as well as a cosmetically or pharmaceutically acceptable addition salt thereof.

Hair loss description

The invention relates to compositions intended for use, in particular in topical application, for retarding hair loss and for inducing and stimulating its growth, containing 2-aminopyrimidine 3-oxide derivatives, as well as to new 2-aminopyrimidine 3-oxide derivatives used in these compositions.

2,4-Diamino-6-piperidinopyrimidine 3-oxide or "minoxidil" is already known in the prior art for its properties as an antihypertensive agent, but also for its use in the treatment of hair loss, pelade, desquamating dermatitis and alopecia.

The Applicant has discovered new compositions for the treatment and prevention of hair loss, used, in particular, in topical application and especially efficacious in the treatment of diseases of the scalp as a result of a particular family of compounds derived from 2-aminopyrimidine 3-oxide.

The compounds selected by the Applicant, in addition to the fact that they are efficacious for hair regrowth and, in particular, for inducing and stimulating its growth and retarding its loss, exhibit substantially zero antihypertensive activity, or an activity lower than that of minoxidil.

These compounds possess solubilities in the media customarily used in cosmetics and in pharmacy which are markedly greater than those of minoxidil.

The subject of the invention is hence new compositions intended for the treatment and prevention of hair loss, containing particular compounds derived from 2-aminopyrimidine 3-oxide.

The subject of the invention is also new derivatives of 2-aminopyrimidine 3-oxide used in these compositions.

Another subject relates to the use of the compounds according to the invention for the preparation of a medicinal product intended for the therapeutic treatment of hair loss.

Other subjects of the invention will become apparent on reading the description and the examples which follow.

The compositions according to the invention are essentially characterized in that they contain, in a physiologically acceptable medium, at least one compound corresponding to the following formula: ##STR6## in which:

R denotes a hydrogen atom or a saturated linear C.sub.1 -C.sub.8 alkyl radical or, with the pyrimidine ring, forms a carbon/hydrogen-containing ring of formula: ##STR7## with n equal to 1, 2 or 3;

X denotes:

(i) a hydrogen atom;

(ii) a group ##STR8##

R.sub.1 and R.sub.2, which may be identical or different, denote a hydrogen atom, a saturated linear or branched C.sub.1 -C.sub.12 alkyl group which can be substituted with a halogen atom or a trifluoromethyl radical, a linear C.sub.2 -C.sub.12 alkenyl group, a C.sub.3 -C.sub.10 cycloalkyl group, a C.sub.7 -C.sub.12 aralkyl group or an aryl group corresponding to the formula: ##STR9## in which R.sub.9 and R.sub.10, which may be identical or different, denote hydrogen, C.sub.1 -C.sub.4 alkyl, hydroxyl, C.sub.1 -C.sub.4 alkoxy or halogen;

R.sub.1 and R.sub.2, with the nitrogen atom to which they are attached, can form a saturated or unsaturated heterocycle selected from the following groups: aziridino, azetidino, pyrrolidino, piperidino, hexamethylenimino, heptamethylenimino, octamethylenimino, tetrahydropyridino, dihydropyridino, pyrrole, pyrrazole, imidazole, triazole, 4-alkylpiperazino, morpholino, thiomorpholino;

(iii) a group --OR.sub.3, in which R.sub.3 denotes a saturated linear or branched C.sub.1 -C.sub.12 alkyl radical which can be substituted with a halogen atom or a trifluoromethyl radical, a linear C.sub.2 -C.sub.12 alkenyl radical, a C.sub.3 -C.sub.10 cycloalkyl radical, a C.sub.7 -C.sub.12 aralkyl radical or a phenyl radical optionally substituted with one or two groups which, independently of one another, denote a C.sub.1 -C.sub.6 alkyl radical, a C.sub.1 -C.sub.6 alkoxy radical, a halogen atom or a trifluoromethyl radical;

(iv) a group --SR.sub.4, in which R.sub.4 has the same meaning as R.sub.3 defined above;

Y denotes an oxygen atom or an --OSO.sub.3.sup..crclbar. group; and

R' denotes a hydrogen atom or one of the following groups: ##STR10## in which:

R.sub.5 and R.sub.6 represent C.sub.1 -C.sub.4 lower alkyl radicals; and

R.sub.7 and R.sub.8 denote a hydrogen atom or a C.sub.1 -C.sub.4 lower alkyl radical, on condition that they do not simultaneously denote a hydrogen atom.

When Y denotes an oxygen atom, the compounds of formula (I) according to the invention can coexist with their tautomeric form of formula (I.sub.2) according to the following equilibrium: ##STR11##

Depending on the nature of the medium, one of the tautomeric forms can be preponderant relative to the other.

The compounds of formula (I) according to the invention may be converted to their cosmetically or pharmaceutically acceptable addition salts with acids, such as the salts with sulphuric, hydrochloric, hydrobromic, phosphoric, acetic, benzoic, salicylic, glycolic, succinic, nicotinic, tartaric, maleic, pamoic, methanesulphonic, picric and lactic acids, and the like.

Among the compounds of general formula (I), a number of compounds are known per se and have been described as antihypertensive agents or as synthesis intermediates.

They are, in particular, described in U.S. Pat. Nos 3,464,987, 3,644,364, 4,013,778 and 4,287,338; French Patent No. 2,087,936; and European Patents EP 058,476 and EP 057,546; or mentioned in the technical literature (Can. J. Chem. 1984, 62(6), 1176-80; Muller, Ramuz, Helv. Chim., Act. 65 (5), 1982, pages 1454-66).

New compounds according to the present invention correspond to the following formula (I'): ##STR12## in which:

R, R' and Y have the same meanings stated in the formula (I) above, and X denotes:

(i) a group --SR.sub.4, in which R.sub.4 denotes a saturated linear or branched C.sub.1 -C.sub.12 alkyl radical which can be substituted with a halogen atom or a trifluoromethyl radical, a linear C.sub.2 -C.sub.12 alkenyl radical, a C.sub.3 -C.sub.10 cycloalkyl radical, a C.sub.7 -C.sub.12 aralkyl radical or a phenyl radical optionally substituted with one or two groups which, independently of one another, denote a halogen atom, a C.sub.1 -C.sub.6 alkyl radical, a C.sub.1 -C.sub.6 alkoxy radical or a trifluoromethyl radical;

(ii) a group --OR.sub.3 in which R.sub.3 has the same meaning as R.sub.4, on condition that, when Y denotes an oxygen atom, R an alkyl group and R' denotes a hydrogen atom, R.sub.3 does not denote a C.sub.1 -C.sub.4 alkyl radical or a phenyl radical optionally substituted with one or two halogen atoms.

The new compounds of formula (I') can occur in the form of physiologically acceptable addition salts with acids.

The compounds according to the present invention corresponding to the general formula (I) are obtained from a 2-aminopyrimidine 3-oxide derivative substituted at the 6-position, of the following formula: ##STR13## in which:

R has the meaning stated in the general formula (I); and

Z denotes a halogen atom selected from chlorine or bromine, a sulphonate group such as tosylate, brosylate or mesylate or a phenoxy group substituted with electron-attracting groups such as halogen atoms or nitro groups.

The particular compounds according to the invention corresponding to the formula (IA): ##STR14## in which R has the meaning stated in the formula (I) above, are obtained by hydrogenolysis of the compounds of formula (II) in which Z more especially denotes a chlorine or bromine atom. The reduction is performed according to the conventional methods described in the technical literature (D. J. Brown, The pyrimidines, Vol. 16, supplement II, Chapter X, 360). The process for preparing them may be represented by the following scheme: ##STR15##

The particular compounds of formula (IB): ##STR16## are obtained by reacting a solution of the alcoholate R.sub.3 O.sup..crclbar. W.sup.61 in which R.sub.3 has the same meaning as that stated for the general formula (I) and W denotes an alkali metal such as sodium, potassium or lithium, in the corresponding alcohol, with the compounds of formula (II) in which Z denotes chlorine or bromine or a phenoxy group substituted with electron-attracting groups.

The Williamson method is applied, as described in European Patent EP 57,546, at a temperature of between 40.degree. and 100.degree. C.

The preparation of these compounds may be represented by the following scheme: ##STR17##

The particular compounds of the following formula (IC): ##STR18## are prepared by reacting the compounds of formula (II) with a thiolate of formula R.sub.4 S.sup..crclbar. W.sup..sym., in which R.sub.4 and W have the meanings stated above, in the presence of a solvent selected from ethers, preferably Methyl cellosolve or ethylene glycol dimethyl ether, at a temperature of the order of 50.degree. to 150.degree. C.

The reaction is performed according to the conventional methods of the literature (D. J. Brown, the PYRIMIDINES, Vol. 16, Supplement II, Chapter VI, Section F).

The preparation of these compounds may be represented by the following scheme: ##STR19##

The particular compounds of the following formula (ID): ##STR20## are obtained by reacting an amine ##STR21## in which R.sub.1 and R.sub.2 have the same meanings as those stated for the general formula (I), with the compounds of formula (II). The reaction is performed in the presence of a solvent which can be an alcohol, preferably ethanol, or the amine serving as a reactant and at the same time as a solvent, at a temperature of between 20.degree. and 1500.degree. C., according to the processes described in U.S. Pat. Nos. 3,644,364 and 3,464,987.

The preparation of these compounds may be represented by the following scheme: ##STR22##

The particular compounds according to the invention of formula (I) in which Y denotes an oxygen atom, obtained according to the different processes described above, may be converted to their O-sulphate homologues by chemical sulphation according to the conventional methods described in the literature (J. Med. Chem. 1983, 26, p. 1791-1793).

The sulphur trioxide/pyridine, sulphur trioxide/triethylamine or sulphur trioxide/ethyldiisopropylamine complexes are used as a sulphating reagent.

The solvents used are preferably dimethylformamide, acetonitrile, chloroform or binary mixtures thereof. The temperature is of the order of 0.degree. to 25.degree. C. and the reaction time varies between 1 hour and 24 hours.

The particular compounds according to the invention of formula (I) in which Y denotes an oxygen atom may be converted to their amide, ureide or carbamate homologues according to the conventional methods described in the literature (J. MARCH, Advanced Organic Chemistry, 3rd edition, p. 370), by the action of an acid chloride, an acid anhydride, a carbamic acid chloride or an alkyl chloroformate, respectively; the reaction is performed in the presence of a tertiary amine such-as pyridine.

The compounds thereby obtained, of formula: ##STR23## in which R, R' and X have the same meaning as that stated for the formula (I) defined above, are readily hydrolyzable, in an alcoholic potassium hydroxide medium for example, and can give rise once more to their precursors of formula (I) in which R' denotes a hydrogen.

The conversion of the compounds of formula (I) in which Y is oxygen and R' is hydrogen to their O-sulphate, amide, ureide or carbamate homologues may be represented by the following scheme: ##STR24##

The compounds of formula (IE) according to the invention can constitute intermediates for the synthesis of the oxadiazolopyrimidines of the following formula (III): ##STR25## in which R and X have the meaning stated in the general formula (I).

The compounds (III) are obtained by internal cyclization/elimination of the carbamate or ureide derivatives of the formula (IE) according to the methods described in the literature (J. C. MULLER, Helvetica Chimica Acta, Vol. 66, 1983, p. 669-672).

The compounds of formula (III) and their salts are new, with the exception of the following compound, namely 2-oxo-2,8-dihydro[1,2,4]oxadiazolo[2,3-a]pyrimidine carbamate which is described in the document (MULLER, RAMUZ, Helvetica Chimica Acta 65 (5), 1982, p. 1454-66) and constitute another subject of the invention. They can receive various applications, and in particular in the use for the treatment and prevention of hair loss.

The compositions according to the present invention, containing, in a physiologically acceptable medium, at least one compound corresponding to the formula (I) or one of its physiologically acceptable addition salts with acids, may be applied in the cosmetic or pharmaceutical field, in particular in topical application. They are intended for the treatment and prevention of hair loss, and in particular of pelade, alopecia and also desquamating dermatitis.

These compositions can contain, by way of a physiologically acceptable medium, any medium suitable for topical application, either in cosmetics or in pharmacy, and which is compatible with the active substance.

The compounds according to the invention can be present in this medium either in the dissolved state or in the dispersed state, in particular in micronized form.

The compositions intended for use in pharmacy are presented in the form of an ointment, tincture, cream, pomade, powder, patch, impregnated pad, solution, emulsion or vesicular dispersion, lotion, gel, spray or suspension. They may be either anhydrous or aqueous, depending on the clinical indication.

The compounds according to the invention are present in these pharmaceutical compositions at concentrations of between 0.1 and 10% by weight, and especially between 0.2 and 5% by weight.

The cosmetic compositions are, in particular, intended for use in the form of a lotion, gel, soap, shampoo, aerosol or foam, and contain, in a cosmetically acceptable vehicle, at least one compound of formula (I) or one of its addition salts with acids.

The concentration of these compounds of formula (I) in these compositions is preferably between 0.01 and 5% by weight, and especially between 0.05 and 3% by weight.

The compositions according to the invention can contain different additives customarily used in cosmetics or in pharmacy, and especially active substances such as hydrating agents, for example thiamorpholinone and its derivatives or urea; antiseborrhoeic agents such as S-carboxymethylcysteine, S-benzylcysteamine and their derivatives; and thioxolone.

The compounds according to the invention may be combined with compounds further improving their activity with respect to hair regrowth and/or to retarding its loss, such as, more especially, the following compounds:

- nicotinic acid esters including, more especially, C.sub.1 -C.sub.6 alkyl nicotinates, and in particular methyl nicotinate;

- steroidal and non-steroidal anti-inflammatory agents well known in the prior art, and especially hydrocortisone, its salts and its derivatives and niflumic acid;

- retinoids, and more especially all-trans-retinoic acid also known as tretinoin, isotretinoin, retinol or vitamin A and its derivatives such as the acetate, palmitate or propionate, motretinide, etretinate and zinc all-trans-retinoate;

- antibacterial agents selected, more especially, from macrolides, pyranosides and tetracyclines, and in particular erythromycin;

- calcium antagonists such as, more especially, cinnarizine and diltiazem;

- hormones such as oestriol or analogues or thyroxine and its salts;

- anti-androgens such as oxendolone, spironolactone and diethylstilboestrol; and

- OH radical-trapping agents such as dimethyl sulphoxide.

It is also possible to combine with the compounds of the invention, where appropriate mixed with the others, compounds such as diazoxide corresponding to 3-methyl-7-chloro-2H-1,2,4-benzothiadiazine 1,1-dioxide; spiroxasoneor7-(acetylthio)-4',5'-dihydrospiro[androst-4-ene-17,2'(3'H)-fu ran]-3-one; phospholipids such as lecithin; linoleic and linolenic acids; salicylic acid and its derivatives described, more especially, in French Patent 2,581,542, and more especially salicylic acid derivatives bearing an alkanoyl group having 2 to 12 carbon atoms at the 5-position of the benzene ring; hydroxy-carboxylic or keto-carboxylic acids and their esters and lactones and their corresponding salts; anthralin or 1,8,9-trihydroxyanthracene; carotenoids; and 5,8,11,14-eicosatetraynoic and 5,8,11-eicosatriynoic acids, their esters and amides.

The compounds according to the invention may also be combined with surfactants including, more especially, those selected from nonionic and amphoteric surfactants.

Among nonionic surfactants, there will be mentioned, more especially, the polyhydroxypropyl ethers described, in particular, in French Patents Nos. 1,477,048, 2,091,516, 2,169,787, 2,328,763 and 2,574,786; oxyethylenated(C.sub.8 -C.sub.9 alkyl)phenols containing from 1 to 100 moles of ethylene oxide, and preferably 5 to 35 moles of ethylene oxide; and alkylpolyglycosides of formula:

in which n varies from 8 to 15 inclusive and x from 1 to 10 inclusive.

Among amphoteric surfactants, there will be mentioned, more especially, the amphocarboxyglycinates and amphocarboxypropionates defined in the CTFA Dictionary, 3rd edition, 1982, and sold, in particular, under the name MIRANOL.RTM. by the company MIRANOL.

The compounds according to the invention may be introduced into vehicles which further improve the activity in respect of regrowth, at the same time possessing advantageous properties from a cosmetic standpoint, such as ternary volatile mixtures of alkylene glycol alkyl ether, especially (C.sub.1 -C.sub.4 alkylene) glycol or dialkylene glycol and preferably (C.sub.1 -C.sub.4 dialkylene) glycol (C.sub.1 -C.sub.4 alkyl) ether, ethyl alcohol and water, the glycol solvent denoting, more especially, ethylene glycol monoethyl ether, propylene glycol monomethyl ether or diethylene glycol monomethyl ether.

The compounds according to the invention may also be introduced into gelled or thickened vehicles, such as essentially aqueous vehicles gelled with heterobiopolysaccharides such as xanthan gum or cellulose derivatives, aqueous-alcoholic vehicles gelled with polyhydroxyethyl acrylates or methacrylates or essentially aqueous vehicles thickened, in particular, with polyacrylic acids crosslinked with a polyfunctional agent, such as the Carbopols sold by the company GOODRICH.

These compositions can also contain preservatives, stabilizers, pH regulators, osmotic pressure-modifying agents, emulsifiers, UV-A and UV-B screening agents and antioxidants such as .alpha.-tocopherol, butylated hydroxyanisole and butylated hydroxytoluene.

The physiologically acceptable medium can consist of water or a mixture of water and a solvent or a mixture of solvents, the solvents being selected from organic solvents which are acceptable from a cosmetic or pharmaceutical standpoint, and selected more especially from C.sub.1 -C.sub.4 lower alcohols such as ethyl alcohol, isopropyl alcohol and tert-butyl alcohol, alkylene glycols and alkylene glycol and dialkylene glycol alkyl ethers such as ethylene glycol monoethyl ether, propylene glycol monomethyl ether and diethylene glycol monomethyl ether. The solvents, if any, are present in proportions of between 1 and 80% by weight relative to the total weight of the composition.

The physiologically acceptable media may be thickened by means of thickening agents customarily used in cosmetics or pharmacy, and heterobiopolysaccharides such as xanthan gum, scleroglucans, cellulose derivatives such as cellulose ethers and acrylic polymers, cross-linked or otherwise, may be mentioned more especially.

The thickeners are preferably present in proportions of between 0.1 and 5% by weight, and especially between 0.4 and 3% by weight, relative to the total weight of the composition.

The subject of the invention is also a process for cosmetic treatment of the hair or scalp, consisting in applying thereon at least one composition as defined above, for the purpose of enhancing the appearance of the hair.

Another subject of the invention consists of the use of the composition containing the compounds of formula (I) defined above, for the preparation of a medicinal product having the effect of inducing or stimulating hair growth and retarding its loss.

The treatment consists chiefly in applying the composition as defined above on the alopecic areas of an individual's scalp.

The preferred method of application consists in applying 1 to 2 g of the composition on the alopecic area at the rate of one or two applications per day for 1 to 7 days per week over a period of 1 to 6 months.

The compositions can, in particular, be used in the treatment of pelade, hair loss and desquamating dermatitis.

The examples which follow are intended as illustrations of the invention, no limitation of the latter, however, being implied.


Photodynamic therapy for the treatment of hair loss
Nutrient composition for preventing hair loss
Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins

7090691 Photodynamic therapy for the treatment of hair loss
7041636 Composition for counteracting hair loss
6762193 Method of treating hair loss
6680344 Method of treating hair loss using diphenylmethane derivatives
6653317 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss
5962508 Retinoid receptor agonists for promoting hair growth and/or retarding hair loss
5919438 Dermatological/cosmetic compositions comprising antifungal and antibacterial compounds and reduction of hair loss therewith
5760043 Process for retarding hair loss and for inducing and stimulating its growth
5728714 Method for treating hair loss using tempo
5723149 Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss
5665335 Combinations of vasoactive substances with fatty acids to prevent hair loss
5650145 Dermatological/cosmetic compositions comprising antifungal and antibacterial compounds and reduction of hair loss therewith
5610302 Composition intended for use for retarding hair loss and for inducing and stimulating its growth, containing 2-aminopyrimidine 3-oxide derivatives, and new compounds derived from 2-aminopyrimidine 3-oxide
5607693 Cosmetic or pharmaceutical composition, especially dermatological composition, containing oxyacanthine, intended in particular for stimulating hair growth or retarding hair loss
5607479 Hair loss replacement method and system
5595564 Device for retarding hair loss and for stimulating its regrowth
5585386 .alpha.-pyrone compositions for inducing/stimulating hair growth and/or retarding hair loss
5567701 Alkylpolyglycoside and pyrimidine derivative based composition for inducing and stimulating hair growth and/or reducing hair loss
5470876 Topical sod for treating hair loss
5466694 Compositions for slowing down hair loss and for inducing and stimulating its growth, based on 24-diamino-pyrimidine 3-oxide derivatives, and new 24-diaminopyrimidine 3-oxide derivatives
5438058 Composition intended to be used for retarding hair loss and for inducing and stimulating hair growth, containing 2-alkyl-4-aminopyrimidine (or 24-dialkylpyrimidine) 3-oxide derivatives and new compounds derived from 2-alkyl-4-aminopyrimidine 3-oxide
5431881 Treatment of hair loss and dermatological problems
5376373 Method of inhibiting radiation induced weight and hair loss
5328914 Use of pyrimidine 3-oxide derivatives for slowing down hair loss and topical compositions used
5215760 Saturated solution of purified sodium chloride in purified aloe vera for inducing and stimulating hair growth and for decreasing hair loss

  Copyright © 2006 - 2015 Patent Information Search